Ben Goldacre @bengoldacre argues that the financial interests of drug companies lead to distorted evidence, but Vincent Lawton believes that adequate safeguards exist to keep bias in check. Full text of the article is published on BMJ Dr Goldacre and Prof Lawton faced each other on the same issue recently as opposing speakers at PharmaTimes’s Great Oxford [...]
Filed under: Next Generation Clinical Trial, Next Generation Drug Discovery | Tagged: collaborative drug development, collaborative drug discovery, health sciences global business unit, Oracle health sciences global business unit | Leave a Comment »











